Literature DB >> 23993439

Optimal medical therapy predicts amputation-free survival in chronic critical limb ischemia.

Jayer Chung1, David A Timaran, J Gregory Modrall, Chul Ahn, Carlos H Timaran, Melissa L Kirkwood, Mirza S Baig, R James Valentine.   

Abstract

OBJECTIVE: Determine the proportion of patients with chronic critical limb ischemia (CLI) who failed to adhere to Trans-Atlantic Inter-Society Consensus II guidelines of medical therapy and to quantify the effect of baseline suboptimal medical management on amputation-free survival (AFS).
METHODS: The patients were identified from a prospectively maintained database of consecutive patients presenting with CLI to the Vascular Surgery service at a single hospital. The primary outcome variable was AFS. The effects of baseline demographics, comorbid medical conditions, ambulatory status, optimal medical management, and Rutherford classification were assessed. Significant univariate predictors (P < .10) of AFS were entered into a multivariate Cox proportional hazards model.
RESULTS: From August 1, 2010 through January 1, 2012, 98 patients (median age, 59.0; interquartile range, 53, 64 years; 58 men) were evaluated with rest pain (n = 40) or tissue loss (n = 58). Optimal medical management was identified in 31 (32%) patients at initial presentation. Compliance rates for the entire cohort were 61% for statin use, 69% for antiplatelet therapy, 56% for angiotensin-converting enzyme inhibitor use, and 53% for beta-blocker use. Significant univariate predictors of major amputation or death included: Rutherford classification (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.01-2.41; P = .04); nonambulatory status (HR, 2.17; 95% CI, 1.68-2.81; P < .01); unrevascularized patients (HR, 2.77; 95% CI, 1.32-5.85; P < .01); a history of tobacco abuse (HR, 1.49; 95% CI, 0.57-3.86; P = .09); a history of end-stage-renal disease (HR, 7.97; 95% CI, 3.10-20.52; P < .01); suboptimal medical management (HR, 4.25; 95% CI, 1.28-14.07; P = .02); and an absence of antiplatelet agents (HR, 1.94; 95% CI, 0.92-4.11; P = .08). Independent predictors of major amputation or death included: initial nonambulatory status (HR, 2.43; 95% CI, 1.03-2.05; P < .01); unrevascularized status (HR, 2.43; 95% CI, 1.76-3.34; P = .01); and suboptimal medical management at presentation (HR, 8.54; 95% CI, 2.05-35.65; P < .01).
CONCLUSIONS: Despite guidelines advocating the optimization of atherosclerotic risk factors, less than one-third of patients with CLI present with their risk factors optimally managed. Patients who are medically undertreated have an eight-fold risk of major amputation and/or death. The magnitude of the effect suggests that future trials and quality assessments should stratify outcomes by the quality of baseline medical management. Of the risk factors affecting AFS medical therapy optimization is the variable that can be most significantly improved by vascular surgeons and the medical community.
Copyright © 2013 Society for Vascular Surgery. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23993439     DOI: 10.1016/j.jvs.2013.03.050

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  14 in total

1.  Endovascular Devices and Revascularization Techniques for Limb-Threatening Ischemia in Individuals With Diabetes.

Authors:  Jayer Chung
Journal:  J Diabetes Sci Technol       Date:  2017-03-28

Review 2.  Promoting Limb Salvage through Multi-Disciplinary Care of the Diabetic Patient.

Authors:  Nichol L Salvo; Mark D Walsh; Luke P Brewster
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-07

3.  An endovascular model of ischemic myopathy from peripheral arterial disease.

Authors:  Chandler A Long; Lucas H Timmins; Panagiotis Koutakis; Traci T Goodchild; David J Lefer; Iraklis I Pipinos; George P Casale; Luke P Brewster
Journal:  J Vasc Surg       Date:  2016-09-29       Impact factor: 4.268

4.  Long-term mortality benefit of renin-angiotensin system inhibitors in patients with chronic limb-threatening ischemia undergoing vascular intervention.

Authors:  Thomas C F Bodewes; Jeremy D Darling; Thomas F X O'Donnell; Sarah E Deery; Katie E Shean; Murray A Mittleman; Frans L Moll; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2017-11-02       Impact factor: 4.268

Review 5.  Building a Critical Limb Ischemia Program.

Authors:  Andrew M Galmer; Samy M Selim; Jay Giri; Joe F Lau; Mitchell D Weinberg
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-08

Review 6.  Preventing Major Amputations in Patients with Critical Limb Ischemia.

Authors:  Eric W Rudofker; Shea E Hogan; Ehrin J Armstrong
Journal:  Curr Cardiol Rep       Date:  2018-07-10       Impact factor: 2.931

7.  Perceptions of patients with wounds due to chronic limb-threatening ischemia.

Authors:  Maria Ceja Rodriguez; John R Mark; Melissa Gosdin; Misty D Humphries
Journal:  Vasc Med       Date:  2021-02-19       Impact factor: 3.239

8.  Post-treatment neutrophil-lymphocyte ratio independently predicts amputation in critical limb ischemia without operation.

Authors:  Han Luo; Ding Yuan; Hongliu Yang; Ma Yukui; Bin Huang; Yi Yang; Fei Xiong; Guojun Zeng; Zhoupeng Wu; Xiyang Chen; Tiehao Wang; Hailong Luo; Jichun Zhao
Journal:  Clinics (Sao Paulo)       Date:  2015-04       Impact factor: 2.365

9.  AG490 suppresses EPO-mediated activation of JAK2-STAT but enhances blood flow recovery in rats with critical limb ischemia.

Authors:  Han-Tan Chai; Hon-Kan Yip; Cheuk-Kwan Sun; Shu-Yuan Hsu; Steve Leu
Journal:  J Inflamm (Lond)       Date:  2016-06-04       Impact factor: 4.981

10.  Immediate results and long-term cardiovascular outcomes of endovascular therapy in octogenarians and nonoctogenarians with peripheral arterial diseases.

Authors:  Hsuan-Li Huang; Jyh-Ming Jimmy Juang; Hsin-Hua Chou; Chien-An Hsieh; Shih-Jung Jang; Shih-Tsung Cheng; Yu-Lin Ko
Journal:  Clin Interv Aging       Date:  2016-05-04       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.